NEW FDA-APPROVED EYEDROPS COULD IMPROVE CLOSE-UP VISION, REPLACE SPECTACLES

Sun 17 July 2022:

Spectacles and eyeglasses are unquestionably a blessing for people with weak eyes. They make it possible for you to read, walk around without tripping over things, and basically just see what is in front of you. They can, however, also be a curse.

They break easily, are very simple to forget at home or in the car, and Covid masks have taught us that they fog up very quickly, effectively blinding you. But what if you weren’t always required to wear those inconvenient glasses? It’s possible if you reside in the United States. A new eye drop that can take the place of glasses has received FDA (Food and Drug Administration) approval.

The product, called Vuity, was approved by the FDA in October and went on the market last week. The new medicine begins working in about 15 minutes and provides sharper vision for 6 to 10 hours.

Vuity is the first FDA-approved eyedrop to treat the condition known as presbyopia, which tends to affect people ages 40 and older. The prescription drug uses the eye’s natural ability to reduce its pupil size.

“Reducing the pupil size expands the depth of field or the depth of focus, and that allows you to focus at different ranges naturally,” George Waring, MD, the lead researcher for the clinical trial, told CBS News.

According to the report, the medication is a formulated form of the well-known compound known as pilocarpine, and the researchers have developed it to quickly adapt to the pH of the tear film.

Utilising the eye’s natural ability to constrict the pupil, the drop enhances near vision while preserving far vision.

The drop is most helpful for people between the ages of 40 and 55, according to the researchers’ analysis of two randomised control trials involving 750 participants.

Moreover, they did not suffer any severe adverse effects; however, a few patients did report minor headaches and eye redness.

SOURCE: INDEPENDENT PRESS AND NEWS AGENCIES

___________________________________________________________________________________________________________________________________________

FOLLOW INDEPENDENT PRESS:

TWITTER (CLICK HERE)
https://twitter.com/IpIndependent